PEGYLATED 6 MG INJECTION

Pegylated 6 mg Injection is a long-acting prescription hematopoietic medicine formulated with pegfilgrastim, a highly effective granulocyte colony-stimulating factor (G-CSF). It is widely used in oncology care to support patients undergoing myelosuppressive chemotherapy by stimulating the bone marrow to produce healthy white blood cells. This advanced formulation plays a critical role in strengthening the immune system during cancer treatment.

This injection is specifically indicated to reduce the duration and severity of chemotherapy-induced neutropenia, a condition marked by dangerously low neutrophil counts. By accelerating neutrophil recovery, Pegylated 6 mg Injection significantly lowers the risk of febrile neutropenia, helping prevent serious infections that may otherwise interrupt cancer therapy or require hospitalization.

With its long-acting pegylated design, Pegylated 6 mg Injection offers sustained protection with fewer injections compared to conventional G-CSF therapies. Administered under medical supervision, it enables patients to continue chemotherapy with greater confidence, improved safety, and reduced infection risk—making it an essential supportive treatment in modern cancer care.

Product Features

• Contains pegfilgrastim, a long-acting granulocyte colony-stimulating factor
• Used to prevent chemotherapy-induced neutropenia and febrile neutropenia
• Stimulates white blood cell production to reduce infection risk
• Supplied as a sterile injectable solution
• Administered by qualified healthcare professionals
• Prescription-only hematology medication

How It Helps

• Stimulates the bone marrow to increase white blood cell (neutrophil) production.
• Reduces the duration of chemotherapy-induced neutropenia.
• Lowers the risk of infections and febrile neutropenia during cancer treatment.
• Helps patients continue chemotherapy on schedule without treatment delays.